Of the 103 patients who completed the Phase III trial, more than half saw remission from a drug-induced condition.
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder <l ...
Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...
Clinical Trials Arena on MSN15d
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adultsNeurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-1140675 in healthy adults. The trial aims to assess ...
Neurocrine Biosciences, Inc. today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback